|1.||Gilat, Tuvia: 6 articles (12/2014 - 08/2003)|
|2.||Konikoff, Fred M: 6 articles (12/2014 - 08/2003)|
|3.||Goldiner, Ilana: 4 articles (08/2010 - 08/2003)|
|4.||Leikin-Frenkel, Alicia: 3 articles (08/2010 - 08/2003)|
|5.||Leikin-Gobbi, Diana: 2 articles (08/2010 - 03/2008)|
|6.||Zelber-Sagi, Shira: 1 article (12/2014)|
|7.||Oren, Ran: 1 article (12/2014)|
|8.||Halpern, Maya: 1 article (12/2014)|
|9.||Mahamid, Mahmud: 1 article (12/2014)|
|10.||FLORA Group: 1 article (12/2014)|
08/01/2003 - "The present study was designed to study the effect of FABAC (arachidyl-amido-cholanoic acid) on diet-induced fatty liver in rats, hamsters, and mice. "
12/01/2014 - "The reduction in liver fat content occurred in a dose-dependent manner and was associated with a trend of metabolic improvements, indicating that Aramchol might be used for the treatment of fatty liver disease. "
08/01/2010 - "The aim of the present study was to investigate whether inhibition of SCD by Aramchol, a fatty acid bile conjugate with known hypocholesterolemic effects, will affect atherogenesis and how. "
08/01/2010 - "In ApoE(-/-), LDRL(-/-) and C57Bl6 mice, the effects of Aramchol on atherogenesis were non-atherogenic. "
06/01/2005 - "In gallstone susceptible mice, Aramchol prevented gallstone formation and dissolved gallstones. "
03/01/2008 - "Gallstone susceptible (C57L/J) mice, on high fat (HFD) or regular diet (RD), were treated with the conjugate of cholic acid with arachidic acid (FABAC; Aramchol). "
10/01/2001 - "Arachidyl amido cholanoic acid (Aramchol) is a cholesterol solubilizer and prevents the formation of cholesterol gallstones in inbred mice."
|4.||Apolipoproteins E (ApoE)
|5.||Adenosine Triphosphate (ATP)
|6.||liver X receptor